Peachtree City, GA [October 17th, 2023] – Huvepharma® is launching VACASAN® (tulathromycin injection), an injectable antibiotic use in beef cattle, non-lactating dairy cattle, and swine. VACASAN® will be available in a 250 mL and 500 mL size, each containing 100 mg of tulathromycin/ mL. Adding VACASAN® not only strengthens the Huvepharma® portfolio of animal health solutions, but provides producers with another tool for overcoming the disease challenges within the livestock production system.
“Respiratory disease in cattle and swine is complex. Producers and veterinarians need choices in the treatment of this economically important syndrome” said Dr. Joe Roder, Director of Huvepharma Cattle Technical Services. “VACASAN® with the rest of the Huvepharma portfolio are great choices for animal health and well-being.”
Tulathromycin is a broad-spectrum antibiotic belonging to the macrolide group of antibiotics. However, it differs from many macrolides and other antibiotics due to its unique chemical structure that provides for a long duration of action. Its pharmacokinetic behavior is characterized by its rapid release from the injection site, fast distribution to the target tissues, and high concentrations at the sites of infection – making it an excellent resource for combatting indicated pathogens.
“Huvepharma is continually focusing on Shaping Livestock Solutions for the benefit of the industry we serve in the US market,” said Dr. Douglas Braun, Senior Product Manager, Huvepharma. “Veterinarians and their clients can be confident when choosing VACASAN® as this newest addition to the Huvepharma portfolio is fully backed by the capable professionals making up the technical and sales support team.”
VACASAN® (tulathromycin injection) in Beef Cattle and Non-Lactating Dairy Cattle is indicated for the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. VACASAN® is also indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis, and the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
VACASAN® (tulathromycin injection) in Suckling Calves, Dairy Calves, and Veal Calves is indicated for the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
VACASAN® (tulathromycin injection) in Swine is approved to treat swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
IMPORTANT SAFETY INFORMATION: VACASAN® (tulathromycin injection): Not for human use. Keep out of reach of children. Do not use in animals previously found to be hypersensitive to the drug. Not for use in chickens or turkeys. Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. This drug is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. Swine intended for human consumption must not be slaughtered within 5 days from the last treatment. Injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter. To report adverse effects, access medical information, or obtain additional product information, call 1-877-994-4883. View product label here
Throughout the U.S., Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 1-877-994-4883 or visit www.huvepharma.us.